Exploring the disease-modifying potential of calcium channel blockers in Parkinson's disease: Using population-based administrative data to inform clinical trials.

探索钙通道阻滞剂治疗帕金森病的疾病缓解潜力：使用基于人群的管理数据为临床试验提供信息。

• 批准号: 172481
• 负责人: Marras Connie
• 金额: $ 21.86万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Salary Programs
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-09-01 至 2013-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=172481&lang=en
• 关键词: Calcium Channel Blockers; Health Care Administrative Databases; Parkinson'S Disease; Prognosis

There is evidence from laboratory models that a class of medication commonly used to treat high blood pressure (dihydropyridine calcium channel blockers, DHP CCBs) may be protective against the progression of Parkinson's disease. This project will explor

实验室模型有证据表明，一类常用于治疗高血压的药物（二氢吡啶类钙通道阻滞剂，DHP CCB）可能对帕金森病的进展具有保护作用。 该项目将探索